TRCT
THRX

Tower Research Capital (TRC)’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,302
Closed -$37.7K – 6307
2023
Q4 		$37.7K Buy
9,302
+3,568
+62% +$10.9K ﹤0.01% 3305
2023
Q3 		$15.4K Buy
5,734
+5,036
+721% +$19.7K ﹤0.01% 3617
2023
Q2 		$6.51K Sell
698
-720
-51% -$7.09K ﹤0.01% 4693
2023
Q1 		$13K Sell
1,418
-3,732
-72% -$36.6K ﹤0.01% 4033
2022
Q4 		$26K Buy
5,150
+730
+17% +$4.28K ﹤0.01% 2901
2022
Q3 		$26K Buy
4,420
+1,757
+66% +$12.4K ﹤0.01% 3735
2022
Q2 		$15K Buy
2,663
+1,255
+89% +$10.4K ﹤0.01% 4109
2022
Q1 		$16K Sell
1,408
-712
-34% -$7.61K ﹤0.01% 3777
2021
Q4 		$27K Buy
+2,120
New +$32K ﹤0.01% 3364

Tower Research Capital (TRC)'s THRX Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 9,302 shares — an estimated $37.7K sold.

Tower Research Capital (TRC) first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $37.7K in Q4 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,302 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $37.7K.
  • Tower Research Capital (TRC) first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Theseus Pharmaceuticals, Inc. Common Stock position peaked at $37.7K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.